Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients

Completed

• Conditions: COVID-19 by SARS-CoV-2 Infection

• Registration Number: NCT04361565
• Lead Sponsor: Centre Hospitalier Universitaire de Nice

Brief Summary

A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-20
• Primary Completion: 2020-04-10
• Study First Submitted: 2020-04-22
• Study First Submitted QC: 2020-04-22
• Study First Posted: 2020-04-24
• Study Completion: 2020-12-31
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-14
• Last Update Posted: 2025-02-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 81

Inclusion Criteria

• COVID-19 diagnosed

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anosmia	45 days	Prevalence for anosmia in the COVID-19 + patients
Ageusia	45 days	Prevalence for ageusia in the COVID-19 + patients
Duration of the loss of anosmia ageusia	45 days	Duration measured in days

Trial Locations

Locations (1)

CHU de Nice; 🇫🇷 Nice, France